Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Atai Life Sciences N.V. (NQ: ATAI ) 1.495 -0.105 (-6.56%) Streaming Delayed Price Updated: 1:44 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 445,667 Open 1.630 Bid (Size) 1.490 (78) Ask (Size) 1.500 (25) Prev. Close 1.600 Today's Range 1.490 - 1.630 52wk Range 1.025 - 2.850 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD July 14, 2024 The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... Via Talk Markets 3 Dirt-Cheap Drug Developers With Blockbuster Potential July 11, 2024 These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. Via InvestorPlace Performance YTD -11.54% -11.54% 1 Month +11.57% +11.57% 3 Month -24.49% -24.49% 6 Month -16.94% -16.94% 1 Year -34.43% -34.43% More News Read More 3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers July 08, 2024 Via InvestorPlace 3 Psychedelic Stocks to Ride to the Moon and Beyond July 06, 2024 Via InvestorPlace Exposures Product Safety Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns July 03, 2024 Via InvestorPlace 3 Psychedelic Stocks to Buy on the Dip: Summer 2024 July 02, 2024 Via InvestorPlace Clinical-Stage BioTech Drug Stocks Declined 13% In June July 01, 2024 Via Talk Markets atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference June 26, 2024 From atai Life Sciences Via GlobeNewswire Largest Clinical-Stage BioTech Drug Stocks Declined 6% June 22, 2024 Via Talk Markets atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a June 20, 2024 From atai Life Sciences Via GlobeNewswire Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why June 09, 2024 Via Talk Markets Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment June 05, 2024 Via Benzinga Exposures Product Safety What's Going On With MindMed And Psychedelic Stocks? June 05, 2024 Via Benzinga atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference May 31, 2024 From atai Life Sciences Via GlobeNewswire atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors May 23, 2024 From atai Life Sciences Via GlobeNewswire ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024 May 15, 2024 Via InvestorPlace atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates May 15, 2024 From atai Life Sciences Via GlobeNewswire Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week May 13, 2024 Via Talk Markets Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon May 09, 2024 Via Benzinga Topics Cannabis Exposures Cannabis Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May May 05, 2024 Via Talk Markets atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression April 24, 2024 From atai Life Sciences Via GlobeNewswire Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week April 23, 2024 Via Talk Markets Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' April 19, 2024 Via Benzinga Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology April 17, 2024 From atai Life Sciences Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
